CEFTAZ-1000
Description
- Broad-spectrum activity against Gram-positive and Gram-negative bacteria
- Ceftriaxone 1000 mg offers strong bactericidal action
- Tazobactam 125 mg inhibits beta-lactamase enzymes, enhancing efficacy
- Effective in respiratory, urinary, intra-abdominal, gynecological, and skin infections
- Administered via IM or IV route under medical supervision
- Useful in both community-acquired and hospital-acquired infections
- Convenient dosing with favorable safety and tolerability profile
Composition
CEFTRIAXONE-1000 MG, TAZOBACTUM-125 MG
Benefits
CEFTAZ-1.125 offers broad-spectrum and enhanced antibacterial efficacy, especially in infections caused by resistant pathogens. By combining Ceftriaxone’s bactericidal properties with Tazobactam’s enzyme-inhibiting action, the formulation ensures improved treatment outcomes in difficult-to-treat infections. It reduces the risk of antibiotic resistance, allows for once or twice-daily dosing, and is well-tolerated by most patients. This makes CEFTAZ-1.125 a preferred antibiotic in both inpatient and outpatient settings, particularly for moderate to severe infections.
Introduction
CEFTAZ-1.125 is a powerful combination antibiotic composed of Ceftriaxone, a third-generation cephalosporin, and Tazobactam, a beta-lactamase inhibitor. This synergistic formulation enhances the spectrum of antibacterial activity by protecting Ceftriaxone from enzymatic degradation by beta-lactamase-producing organisms. CEFTAZ-1.125 is highly effective against a broad range of Gram-positive and Gram-negative bacteria, making it a valuable choice for treating severe and hospital-acquired infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.
